Kenvue (NYSE:KVUE) Posts Earnings Results, Meets Estimates

Kenvue (NYSE:KVUE) issued its earnings results on Friday. The company reported $0.29 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.29, FiscalAI reports. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The firm had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.86 billion. During the same period in the previous year, the firm posted $0.28 earnings per share. The business’s revenue was up 3.2% compared to the same quarter last year.

Kenvue Trading Down 1.5%

Shares of KVUE stock traded down $0.30 on Friday, reaching $19.26. 66,594,959 shares of the company’s stock were exchanged, compared to its average volume of 27,001,805. Kenvue has a 52 week low of $14.06 and a 52 week high of $20.13. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $36.99 billion, a PE ratio of 22.14, a P/E/G ratio of 1.77 and a beta of 0.48. The company’s fifty day simple moving average is $18.39 and its 200 day simple moving average is $18.18.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 2nd. Stockholders of record on Monday, September 21st were paid a dividend of $0.21 per share. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. Kenvue’s dividend payout ratio is currently 96.55%.

Trending Headlines about Kenvue

Here are the key news stories impacting Kenvue this week:

• Positive Sentiment: Revenue increased 3.2% year over year to $3.89 billion, exceeding the roughly $3.86 billion consensus estimate. Management cited continued growth in Self Care and Essential Health, productivity initiatives, margin expansion and strong cash generation. Kenvue Reports Third Quarter 2026 Results
• Positive Sentiment: Reported earnings were $0.29 per share, up from $0.28 a year earlier. Zacks characterized the result as slightly ahead of its $0.28 consensus estimate, while other coverage said profit fell short of expectations, suggesting the market is focused on the exact earnings measure and guidance. Kenvue Surpasses Q3 Earnings Estimates
• Positive Sentiment: The quarterly performance represents Kenvue’s fourth consecutive quarter of net and organic sales growth, supporting management’s efforts to rebuild momentum across its consumer-health brands. Kenvue Profit, Revenue Rise as Turnaround Efforts Continue
• Neutral Sentiment: Kenvue’s results arrive as its approximately $40 billion acquisition by Kimberly-Clark approaches closing. The deal may provide strategic support, but investors remain focused on execution, integration and the turnaround’s durability. Kenvue Q3 2026 Revenue Beats as Kimberly-Clark Deal Nears Close
• Negative Sentiment: The conflicting earnings headlines indicate that profit performance did not clearly exceed investor expectations, even though revenue beat forecasts. Earlier concerns about inflation and cautious consumer spending also remain potential pressures on margins and demand. Kenvue Misses Third-Quarter Profit Expectations

Wall Street Analyst Weigh In

A number of equities analysts recently commented on KVUE shares. Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. HSBC reduced their price objective on Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Barclays increased their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Thirteen analysts have rated the stock with a Hold rating. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $19.33.

About Kenvue

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.